Transfusion of Blood Products and Clinical Outcomes for Patients With Dengue Fever: A Systematic Review and Meta-analysis

Zhi Jie Goh,Ruiqi Li,Min Xian Wang,Po Ying Chia,Jue Tao Lim
DOI: https://doi.org/10.1093/ofid/ofae507
2024-08-30
Open Forum Infectious Diseases
Abstract:Abstract Background This systematic review and meta-analysis aimed to analyze the effects of transfusing “nonpacked red blood cell” blood products in patients with dengue and evaluate the effectiveness in reducing mean hospital stay, bleeding, mortality rate, and intensive care unit requirements. Methods Four databases were searched for relevant articles. Inclusion criteria were prospective or retrospective randomized or nonrandomized studies investigating the effects of transfusion of blood products in patients with dengue. Results Nine studies were included in the final meta-analysis. Transfusion of blood products was associated with significantly higher mortality rate (9 studies; odds ratio [OR], 3.59 [95% confidence interval [CI], 1.07–15.98]; I2 = 0%; P = .04) and significantly longer mean hospital stay (6 studies; 0.56 day [95% CI, .03–1.08 day]; I2 = 95%; P = .04). There was no significant difference in the incidence of clinical bleeding (7 studies; OR, 1.13 [95% CI, .77–1.65]; I2 = 39%; P = .54) or intensive care unit requirement (3 studies; OR, 1.59 [.40–6.39]; I2 = 0%; P = .51). Conclusions Transfusing blood products for patients with dengue showed no benefit and may even be harmful.
immunology,infectious diseases,microbiology
What problem does this paper attempt to address?